4.5245

2.29% -0.0655

Emergent Biosolutions Inc (EBS)

Overview News Price History Option Chain Discussions Forecast

Emergent Biosolutions Inc stock is traded at $4.5245, with a volume of 458.07K. It is down -2.29% in the last 24 hours and down -41.22% over the past month. Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Previous Close:

$4.59

Open:

$4.5

24h Volume:

458.07K

Relative Volume:

0.47

Market Cap:

$232.01M

Revenue:

$676.80M

Net Income/Loss:

$-8.60M

P/E Ratio:

-15.99

EPS:

-0.2829

Net Cash Flow:

$135.40M

1W Performance:

+0.34%

1M Performance:

-41.22%

6M Performance:

-58.08%

1Y Performance:

-49.26%

1-Day Range:

$4.43

$4.58

1-Week Range:

$4.3699

$4.73

52-Week Range:

$4.36

$14.06

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name

Emergent Biosolutions Inc

Sector

Healthcare (1089)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

240-631-3200

Address

300 PROFESSIONAL DR, GAITHERSBURG, MD

Employee

900

Twitter

@emergentbiosolu

Next Earnings Date

2026-08-05

Latest SEC Filings

EBS's Discussions on Twitter

Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EBS Emergent Biosolutions Inc	4.525	235.34M	676.80M	-8.60M	135.40M	-0.2829
TAK Takeda Pharmaceutical Co Adr	17.36	56.30B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.48	42.85B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.5825	42.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	72.72	30.49B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	507.49	21.43B	3.17B	1.29B	1.01B	27.09

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-22-24	Initiated	Rodman & Renshaw	Buy
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-14-20	Resumed	JP Morgan	Neutral
Jul-31-20	Reiterated	Chardan Capital Markets	Buy
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-02-18	Upgrade	Goldman	Neutral → Buy
Aug-03-18	Reiterated	Chardan Capital Markets	Buy
Jun-13-18	Initiated	Argus	Buy
Apr-25-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-24-18	Initiated	Goldman	Neutral
Jan-16-18	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	Singular Research	Buy
Apr-15-16	Initiated	Chardan Capital Markets	Buy
Mar-28-16	Initiated	Singular Research	Buy
Feb-19-16	Initiated	Wells Fargo	Outperform
May-15-14	Initiated	Summer Street Research	Buy
May-31-11	Reiterated	WBB Securities	Strong Buy
Jan-10-11	Reiterated	Wedbush	Outperform
Nov-05-10	Reiterated	Wedbush	Outperform
Aug-18-10	Upgrade	WBB Securities	Buy → Strong Buy
Aug-06-10	Reiterated	Caris & Company	Buy

View All

Emergent Biosolutions Inc Stock (EBS) Latest News

01:38 AM

EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law - lincolnjournal.com

01:38 AM

12:52 PM

Emergent BioSolutions Restructures - Contract Pharma

12:52 PM

10:09 AM

Emergent BioSolutions (EBS) Securities Investigation NoticeLevi & Korsinsky - PR Newswire

10:09 AM

Aug 16, 2026

Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts - MarketBeat

Aug 16, 2026

Aug 15, 2026

Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus

Aug 15, 2026

Aug 14, 2026

American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G - Stock Titan

Aug 14, 2026

Emergent Biosolutions (EBS) Earnings Date and Reports 2026 $EBS - MarketBeat

Aug 14, 2026

Aug 13, 2026

Levi & Korsinsky Notifies Investors of Pending - GlobeNewswire

Aug 13, 2026

Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research - MarketBeat

Aug 13, 2026

Aug 12, 2026

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript - AOL.com

Aug 12, 2026

EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS) - Business Wire

Aug 12, 2026

Emergent BioSolutions (EBS) EVP Stephanie Duatschek details stock and option holdings - Stock Titan

Aug 12, 2026

Aug 11, 2026

Trade Desk, Papa John's, Emergent BioSolutions Hit 52-Week Lows as Weak Results Trigger Analyst Downgrades - finance.biggo.com

Aug 11, 2026

EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions - PR Newswire

Aug 11, 2026

EMERGENT BIOSOLUTIONS INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $10 FROM $12 - webull.com

Aug 11, 2026

Why Did TTD, PZZA, EBS Stocks Plummet To 52 Week Lows? - Stocktwits

Aug 11, 2026

Aug 10, 2026

Emergent BioSolutions cuts FY2026 revenue forec... - Pluang

Aug 10, 2026

Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS) - PR Newswire

Aug 10, 2026

H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo

Aug 10, 2026

H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue outlook - Investing.com Nigeria

Aug 10, 2026

Emergent Biosolutions (NYSE:EBS) Given New $10.00 Price Target at HC Wainwright - MarketBeat

Aug 10, 2026

EBS Maintained by HC Wainwright & Co. -- Price Target Lowered to $10 - GuruFocus

Aug 10, 2026

Aug 09, 2026